Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments
Launched by SUNNYBROOK HEALTH SCIENCES CENTRE · Oct 12, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment for people who still feel unwell after recovering from COVID-19, a condition often called post COVID-19 syndrome. Many individuals experience ongoing symptoms like chronic fatigue, which is a constant feeling of tiredness and low energy. The trial will test a treatment called hyperbaric oxygen therapy, where patients spend time in a special chamber that delivers high levels of oxygen. This therapy may help reduce fatigue and improve overall well-being.
To participate in the trial, you must be at least 18 years old, have been officially diagnosed with post COVID-19 syndrome by a doctor, and have been experiencing symptoms for more than 12 weeks after your COVID-19 infection. Patients who have certain health issues, such as severe heart problems or other serious medical conditions, may not be eligible. If you join the study, you can expect to receive the hyperbaric oxygen therapy and help researchers understand if this treatment is effective for alleviating symptoms of post COVID-19 syndrome. The findings could lead to larger studies in the future, helping many people who are struggling with ongoing health issues after COVID-19.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years old
- • 2. Officially diagnosed with post COVID-19 condition by a healthcare practitioner
- • 3. At least three months since SARS-CoV-2 infection
- 4. Symptoms that persist more than 12 weeks:
- * Chronic fatigue (must include) along with one of the following symptoms:
- • Difficulty thinking or problem solving ('brain fog')
- • Stress or anxiety
- Exclusion Criteria:
- • 1. Contraindications/medically unfit to receive hyperbaric treatments at an outpatient facility (pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)
- • 2. Patients with cognitive difficulties and/or mental retardation before COVID diagnosis
- • 3. History of traumatic brain injury
- • 4. Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)
- • 5. Known pregnancy or planning a pregnancy in women of childbearing age
About Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre is a leading academic health science organization located in Toronto, Canada, renowned for its commitment to advancing patient care through innovative research and education. As a prominent clinical trial sponsor, Sunnybrook integrates cutting-edge medical research with clinical practice, focusing on a wide range of health disciplines, including cancer care, trauma, and cardiovascular health. The center collaborates with various stakeholders, including academic institutions, healthcare providers, and industry partners, to facilitate the development of novel therapies and improve health outcomes. With a robust infrastructure and a dedicated team of researchers and clinicians, Sunnybrook plays a pivotal role in translating scientific advancements into tangible benefits for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Fahad Alam, MD
Principal Investigator
Sunnybrook Health Sciences Centre
Jordan Tarshis, MD
Principal Investigator
Sunnybrook Health Sciences Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported